Compare ResMed Inc. (RMD) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? ResMed Inc. trades at $194.03 (market cap $28.81B), while Direxion Daily S&P 500 Bull 3X Shares trades at $270.48. The key difference: ResMed Inc. pays a 1.21% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | SPXL | |
|---|---|---|
Market Cap | $28.81B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $293.73 | $288.04 |
52-Week Low | $182.82 | $170.20 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
SPXL is trading at $264.57, down 0.44% with a bearish technical signal. The ETF faces resistance at the 50-day moving average while support levels cluster around $262-$254. Recent news highlights S&P 500 valuation concerns with Shiller CAPE ratios approaching historic highs, creating headwinds for leveraged index products.
The leveraged ETF's performance remains tied to S&P 500 momentum amid mixed earnings sentiment. Key risks include market concentration in tech stocks and potential AI bubble concerns, while institutional analysis suggests the broader market may still deliver double-digit gains through 2026 despite valuation pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
